U.S. Markets close in 2 hrs 49 mins
  • S&P 500

    4,527.05
    -50.05 (-1.09%)
     
  • Dow 30

    34,539.00
    -100.79 (-0.29%)
     
  • Nasdaq

    15,033.70
    -347.62 (-2.26%)
     
  • Russell 2000

    2,161.23
    -45.10 (-2.04%)
     
  • Crude Oil

    66.87
    +0.37 (+0.56%)
     
  • Gold

    1,782.10
    +19.40 (+1.10%)
     
  • Silver

    22.47
    +0.15 (+0.69%)
     
  • EUR/USD

    1.1312
    +0.0006 (+0.0566%)
     
  • 10-Yr Bond

    1.3720
    -0.0760 (-5.25%)
     
  • Vix

    31.46
    +3.51 (+12.56%)
     
  • GBP/USD

    1.3237
    -0.0065 (-0.4911%)
     
  • USD/JPY

    112.8470
    -0.3620 (-0.3198%)
     
  • BTC-USD

    55,090.08
    -1,384.74 (-2.45%)
     
  • CMC Crypto 200

    1,398.80
    -42.96 (-2.98%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Dicerna Starts Dosing With Nedosiran In Primary Hyperoxaluria Early-Stage Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) initiates patient dosing in Phase 1 PHYOX 4 trial evaluating its lead candidate, nedosiran, to treat primary hyperoxaluria, a rare condition characterized by the recurrent kidney and bladder stones. The condition often results in end-stage renal disease.

  • The study will evaluate the safety and efficacy of a single dose of nedosiran and assess the proportion of participants achieving more than a 30% decrease from baseline in 24-hour urinary oxalate on two consecutive visits.

  • The trial is expected to enroll six participants aged six years and above, and results are expected in mid-2021.

  • PHYOX4 participants who respond to treatment with nedosiran and complete the trial are eligible to enroll in the Company's PHYOX3 trial, an ongoing open-label extension study evaluating nedosiran's long-term safety and efficacy.

  • Nedosiran marketing application submission is anticipated in the third quarter of 2021.

  • Price Action: DRNA moved 0.46 higher at $26 during market hours on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.